Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 1/2013

01-01-2013 | Original Article

Association between estrogen receptor-β dinucleotide repeat polymorphism and incidence of femoral fracture

Authors: Naoko Honma, Seijiro Mori, Heying Zhou, Shinobu Ikeda, Makiko Naka Mieno, Noriko Tanaka, Kaiyo Takubo, Tomio Arai, Motoji Sawabe, Masaaki Muramatsu, Hideki Ito

Published in: Journal of Bone and Mineral Metabolism | Issue 1/2013

Login to get access

Abstract

Estrogens are thought to play an important role in bone metabolism through estrogen receptors (ER). Dinucleotide (cytosine–adenine, CA) repeat polymorphism in the human ER-β gene (ESR2) has been reported to be associated with bone mineral density. We aimed to further elucidate the importance of this polymorphism in the pathogenesis of osteoporosis by examining its association with the incidence of femoral fracture. Deoxyribonucleic acids extracted from the renal cortex of 1489 consecutive Japanese autopsies (799 male, mean age 79 years, 690 female, mean age 82 years) with complete clinical/pathological data were enrolled in the study. ESR2 CA repeat polymorphism was determined by polymerase chain reaction using fluorescein-labeled primers. The presence or absence of femoral fracture during each subject’s lifetime was determined by thorough examination of the clinical record. Incidence of femoral fracture in subjects bearing at least one allele of 20 CA repeats (4/132, 3.0 %) was significantly lower than in those without this allele (127/1357, 9.4 %, P = 0.0098). After adjustments for age and sex, logistic regression analysis revealed that having no allele of 20 CA repeats was an independent risk factor of femoral fracture [adjusted odds ratio (OR) 3.875, 95 % confidence interval (CI) 1.392–10.788, P = 0.0095], which was emphasized among women (adjusted OR 6.360, 95 % CI 1.520–26.618, P = 0.0133). Japanese subjects, especially women, bearing at least one allele of 20 CA repeats in the ESR2 may have a lower risk of femoral fracture than those without it, suggesting this polymorphism plays a role in bone metabolism.
Literature
1.
go back to reference Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337PubMedCrossRef Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337PubMedCrossRef
2.
go back to reference Albagha OM, Ralston SH (2003) Genetic determinants of susceptibility to osteoporosis. Endocrinol Metab Clin N Am 32:65–81, vi Albagha OM, Ralston SH (2003) Genetic determinants of susceptibility to osteoporosis. Endocrinol Metab Clin N Am 32:65–81, vi
3.
4.
go back to reference Hirschhorn JN, Gennari L (2008) Bona fide genetic associations with bone mineral density. N Engl J Med 358:2403–2405PubMedCrossRef Hirschhorn JN, Gennari L (2008) Bona fide genetic associations with bone mineral density. N Engl J Med 358:2403–2405PubMedCrossRef
5.
go back to reference Ralston SH, de Crombrugghe B (2006) Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev 20:2492–2506PubMedCrossRef Ralston SH, de Crombrugghe B (2006) Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev 20:2492–2506PubMedCrossRef
6.
go back to reference Khosla S, Melton LJ 3rd, Atkinson EJ, O’Fallon WM (2001) Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86:3555–3561PubMedCrossRef Khosla S, Melton LJ 3rd, Atkinson EJ, O’Fallon WM (2001) Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86:3555–3561PubMedCrossRef
7.
go back to reference Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC (1997) Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 100:1755–1759PubMedCrossRef Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC (1997) Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 100:1755–1759PubMedCrossRef
8.
go back to reference Ettinger B, Genant HK, Cann CE (1985) Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 102:319–324PubMed Ettinger B, Genant HK, Cann CE (1985) Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 102:319–324PubMed
9.
go back to reference Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC (1976) Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1:1038–1041PubMedCrossRef Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC (1976) Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1:1038–1041PubMedCrossRef
10.
go back to reference Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925–5930PubMedCrossRef Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925–5930PubMedCrossRef
11.
go back to reference Mosselman S, Polman J, Dijkema R (1996) ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49–53PubMedCrossRef Mosselman S, Polman J, Dijkema R (1996) ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49–53PubMedCrossRef
12.
go back to reference Arts J, Kuiper GG, Janssen JM, Gustafsson JA, Lowik CW, Pols HA, van Leeuwen JP (1997) Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 138:5067–5070PubMedCrossRef Arts J, Kuiper GG, Janssen JM, Gustafsson JA, Lowik CW, Pols HA, van Leeuwen JP (1997) Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 138:5067–5070PubMedCrossRef
13.
go back to reference Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T (1997) Expression of estrogen receptor beta in rat bone. Endocrinology 138:4509–4512PubMedCrossRef Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T (1997) Expression of estrogen receptor beta in rat bone. Endocrinology 138:4509–4512PubMedCrossRef
14.
go back to reference Tsukamoto K, Inoue S, Hosoi T, Orimo H, Emi M (1998) Isolation and radiation hybrid mapping of dinucleotide repeat polymorphism at the human estrogen receptor beta locus. J Hum Genet 43:73–74PubMedCrossRef Tsukamoto K, Inoue S, Hosoi T, Orimo H, Emi M (1998) Isolation and radiation hybrid mapping of dinucleotide repeat polymorphism at the human estrogen receptor beta locus. J Hum Genet 43:73–74PubMedCrossRef
15.
go back to reference Geng L, Yao Z, Yang H, Luo J, Han L, Lu Q (2007) Association of CA repeat polymorphism in estrogen receptor beta gene with postmenopausal osteoporosis in Chinese. J Genet Genomics 34:868–876PubMedCrossRef Geng L, Yao Z, Yang H, Luo J, Han L, Lu Q (2007) Association of CA repeat polymorphism in estrogen receptor beta gene with postmenopausal osteoporosis in Chinese. J Genet Genomics 34:868–876PubMedCrossRef
16.
go back to reference Lau HH, Ho AY, Luk KD, Kung AW (2002) Estrogen receptor beta gene polymorphisms are associated with higher bone mineral density in premenopausal, but not postmenopausal southern Chinese women. Bone 31:276–281PubMedCrossRef Lau HH, Ho AY, Luk KD, Kung AW (2002) Estrogen receptor beta gene polymorphisms are associated with higher bone mineral density in premenopausal, but not postmenopausal southern Chinese women. Bone 31:276–281PubMedCrossRef
17.
go back to reference Ogawa S, Hosoi T, Shiraki M, Orimo H, Emi M, Muramatsu M, Ouchi Y, Inoue S (2000) Association of estrogen receptor beta gene polymorphism with bone mineral density. Biochem Biophys Res Commun 269:537–541PubMedCrossRef Ogawa S, Hosoi T, Shiraki M, Orimo H, Emi M, Muramatsu M, Ouchi Y, Inoue S (2000) Association of estrogen receptor beta gene polymorphism with bone mineral density. Biochem Biophys Res Commun 269:537–541PubMedCrossRef
18.
go back to reference Scariano JK, Simplicio SG, Montoya GD, Garry PJ, Baumgartner RN (2004) Estrogen receptor beta dinucleotide (CA) repeat polymorphism is significantly associated with bone mineral density in postmenopausal women. Calcif Tissue Int 74:501–508PubMedCrossRef Scariano JK, Simplicio SG, Montoya GD, Garry PJ, Baumgartner RN (2004) Estrogen receptor beta dinucleotide (CA) repeat polymorphism is significantly associated with bone mineral density in postmenopausal women. Calcif Tissue Int 74:501–508PubMedCrossRef
19.
go back to reference Shearman AM, Karasik D, Gruenthal KM, Demissie S, Cupples LA, Housman DE, Kiel DP (2004) Estrogen receptor beta polymorphisms are associated with bone mass in women and men: the Framingham Study. J Bone Miner Res 19:773–781PubMedCrossRef Shearman AM, Karasik D, Gruenthal KM, Demissie S, Cupples LA, Housman DE, Kiel DP (2004) Estrogen receptor beta polymorphisms are associated with bone mass in women and men: the Framingham Study. J Bone Miner Res 19:773–781PubMedCrossRef
20.
go back to reference Takeo C, Ugai K, Araki J, Zhang L, Baba M, Ohashi W, Ueno K, Suzuki Y, Amano K, Hirai A, Muramatsu M (2008) Pharmacogenetics of hormone replacement therapy for climacteric symptoms. Biochem Biophys Res Commun 374:604–608PubMedCrossRef Takeo C, Ugai K, Araki J, Zhang L, Baba M, Ohashi W, Ueno K, Suzuki Y, Amano K, Hirai A, Muramatsu M (2008) Pharmacogenetics of hormone replacement therapy for climacteric symptoms. Biochem Biophys Res Commun 374:604–608PubMedCrossRef
21.
go back to reference Forsell C, Enmark E, Axelman K, Blomberg M, Wahlund LO, Gustafsson JA, Lannfelt L (2001) Investigations of a CA repeat in the oestrogen receptor beta gene in patients with Alzheimer’s disease. Eur J Hum Genet 9:802–804PubMedCrossRef Forsell C, Enmark E, Axelman K, Blomberg M, Wahlund LO, Gustafsson JA, Lannfelt L (2001) Investigations of a CA repeat in the oestrogen receptor beta gene in patients with Alzheimer’s disease. Eur J Hum Genet 9:802–804PubMedCrossRef
22.
go back to reference Slattery ML, Sweeney C, Murtaugh M, Ma KN, Wolff RK, Potter JD, Caan BJ, Samowitz W (2005) Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 14:2936–2942PubMedCrossRef Slattery ML, Sweeney C, Murtaugh M, Ma KN, Wolff RK, Potter JD, Caan BJ, Samowitz W (2005) Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 14:2936–2942PubMedCrossRef
23.
go back to reference Westberg L, Baghaei F, Rosmond R, Hellstrand M, Landen M, Jansson M, Holm G, Bjorntorp P, Eriksson E (2001) Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J Clin Endocrinol Metab 86:2562–2568PubMedCrossRef Westberg L, Baghaei F, Rosmond R, Hellstrand M, Landen M, Jansson M, Holm G, Bjorntorp P, Eriksson E (2001) Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J Clin Endocrinol Metab 86:2562–2568PubMedCrossRef
24.
go back to reference Sakuma M, Endo N, Oinuma T, Endo E, Yazawa T, Watanabe K, Watanabe S (2008) Incidence and outcome of osteoporotic fractures in 2004 in Sado City, Niigata Prefecture, Japan. J Bone Miner Metab 26:373–378PubMedCrossRef Sakuma M, Endo N, Oinuma T, Endo E, Yazawa T, Watanabe K, Watanabe S (2008) Incidence and outcome of osteoporotic fractures in 2004 in Sado City, Niigata Prefecture, Japan. J Bone Miner Metab 26:373–378PubMedCrossRef
25.
go back to reference Shimokata H (2004) Epidemiological statistics of dementia in Japan. Nihon Rinsho 62:121–126PubMed Shimokata H (2004) Epidemiological statistics of dementia in Japan. Nihon Rinsho 62:121–126PubMed
26.
go back to reference Ugai K, Nishimura K, Fukino K, Nakamura T, Ueno K (2008) Functional analysis of transcriptional activity of cytosine and adenine (CA) repeats polymorphism in the estrogen receptor beta gene. J Toxicol Sci 33:237–240PubMedCrossRef Ugai K, Nishimura K, Fukino K, Nakamura T, Ueno K (2008) Functional analysis of transcriptional activity of cytosine and adenine (CA) repeats polymorphism in the estrogen receptor beta gene. J Toxicol Sci 33:237–240PubMedCrossRef
27.
go back to reference Poola I, Abraham J, Baldwin K (2002) Identification of ten exon deleted ERbeta mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor beta mRNA is distinct from that of estrogen receptor alpha. FEBS Lett 516:133–138PubMedCrossRef Poola I, Abraham J, Baldwin K (2002) Identification of ten exon deleted ERbeta mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor beta mRNA is distinct from that of estrogen receptor alpha. FEBS Lett 516:133–138PubMedCrossRef
Metadata
Title
Association between estrogen receptor-β dinucleotide repeat polymorphism and incidence of femoral fracture
Authors
Naoko Honma
Seijiro Mori
Heying Zhou
Shinobu Ikeda
Makiko Naka Mieno
Noriko Tanaka
Kaiyo Takubo
Tomio Arai
Motoji Sawabe
Masaaki Muramatsu
Hideki Ito
Publication date
01-01-2013
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 1/2013
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-012-0383-z

Other articles of this Issue 1/2013

Journal of Bone and Mineral Metabolism 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.